Nkarta, Inc.
(NASDAQ: NKTX)

Nkarta, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of natural killer cell therapies for the treatment of cancer. The firm’s product include NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes, and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company was founded by Dario Campana in 2005 and is headquartered in South San Francisco, CA.

1.840

+0.060 (+3.37%)
Range 1.750 - 1.850   (5.71%)
Open 1.775
Previous Close 1.780
Bid Price 4.480
Bid Volume 9
Ask Price 4.500
Ask Volume 10
Volume 707,104
Value -
Remark
Delayed prices. Updated at 05 Dec 2025 05:00.
Data powered by
View All Events


Loading Chart...

Please login to view stock data and analysis